Literature DB >> 12505059

NF-kappaB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells.

Peter Zahradka1, Jeffrey P Werner, Shelly Buhay, Brenda Litchie, Gail Helwer, Shawn Thomas.   

Abstract

Angiotensin II (AngII) functions as a stress hormone under conditions of stretch, pressure and injury to stimulate smooth muscle cell migration and proliferation. Since the cellular response to stress is mediated in part by the transcription factor NF-kappaB, the relationship between AngII and NF-kappaB was investigated. Our study revealed that AngII promoted a dose-dependent and transient phosphorylation of the regulatory IkappaBalpha protein in smooth muscle cells from porcine coronary artery, with concomitant nuclear translocation of NF-kappaB and increased binding to a kappaB promoter element. Both nuclear translocation and kappaB-element binding were prevented by the AT(1) receptor antagonist losartan. The role of NF-kappaB in AngII-dependent smooth muscle cell migration and proliferation was then assessed. Inhibitors of NF-kappaB nuclear translocation (phenethyl caffeiate) and IkappaB phosphorylation (Bay 11-7085) effectively arrested both AngII-dependent DNA synthesis and migration. These results were confirmed with SN50, a highly selective peptide inhibitor of NF-kappaB activation. Phenethyl caffeiate also prevented the phosphorylation of cdk2 and Rb, indicating NF-kappaB was required for G1/S transition. The target of NF-kappaB inhibition was identified as cyclin E, since induction of this gene, but not cyclin D1, was suppressed by phenethyl caffeiate. We subsequently examined the relationship between NF-kappaB and neointimal formation in response to angioplasty-induced injury, a process susceptible to inhibition by losartan. Both phenethyl caffeiate and Bay 11-7085 blocked neointimal hyperplasia in organ culture following balloon angioplasty. These data indicate NF-kappaB is an important mediator of intracellular signalling by AngII under normal physiological conditions, and following vascular injury.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12505059     DOI: 10.1006/jmcc.2002.2111

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  24 in total

Review 1.  Ca2+, calmodulin, and cyclins in vascular smooth muscle cell cycle.

Authors:  Vera V Koledova; Raouf A Khalil
Journal:  Circ Res       Date:  2006-05-26       Impact factor: 17.367

Review 2.  Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?

Authors:  Michael J Osgood; David G Harrison; Kevin W Sexton; Kyle M Hocking; Igor V Voskresensky; Padmini Komalavilas; Joyce Cheung-Flynn; Raul J Guzman; Colleen M Brophy
Journal:  Ann Vasc Surg       Date:  2012-03-22       Impact factor: 1.466

Review 3.  Crosstalk between the renin-angiotensin system and the advance glycation end product axis in the heart: role of the cardiac fibroblast.

Authors:  Katrina Go Yamazaki; Eileen Gonzalez; Alexander C Zambon
Journal:  J Cardiovasc Transl Res       Date:  2012-09-29       Impact factor: 4.132

4.  A Novel Systems-Biology Algorithm for the Analysis of Coordinated Protein Responses Using Quantitative Proteomics.

Authors:  Fernando García-Marqués; Marco Trevisan-Herraz; Sara Martínez-Martínez; Emilio Camafeita; Inmaculada Jorge; Juan Antonio Lopez; Nerea Méndez-Barbero; Simón Méndez-Ferrer; Miguel Angel Del Pozo; Borja Ibáñez; Vicente Andrés; Francisco Sánchez-Madrid; Juan Miguel Redondo; Elena Bonzon-Kulichenko; Jesús Vázquez
Journal:  Mol Cell Proteomics       Date:  2016-02-18       Impact factor: 5.911

Review 5.  New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease.

Authors:  Anjay Rastogi; Farid Arman; Setareh Alipourfetrati
Journal:  Curr Hypertens Rep       Date:  2016-07       Impact factor: 5.369

6.  Activation of peroxisome proliferator-activated receptors alpha and gamma1 inhibits human smooth muscle cell proliferation.

Authors:  Peter Zahradka; Natalia Yurkova; Brenda Litchie; Michael C Moon; Dario F Del Rizzo; Carla G Taylor
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

7.  Myocardin inhibits cellular proliferation by inhibiting NF-kappaB(p65)-dependent cell cycle progression.

Authors:  Ru-Hang Tang; Xi-Long Zheng; Thomas E Callis; William E Stansfield; Jiayin He; Albert S Baldwin; Da-Zhi Wang; Craig H Selzman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-22       Impact factor: 11.205

8.  Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration.

Authors:  Yujun Cai; Walter E Knight; Shujie Guo; Jian-Dong Li; Peter A Knight; Chen Yan
Journal:  J Pharmacol Exp Ther       Date:  2012-08-22       Impact factor: 4.030

9.  The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.

Authors:  A C Calkin; S Giunti; K J Sheehy; C Chew; V Boolell; Y S Rajaram; M E Cooper; K A Jandeleit-Dahm
Journal:  Diabetologia       Date:  2008-07-02       Impact factor: 10.122

10.  Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury.

Authors:  Bian Wu; Giorgio Mottola; Anuran Chatterjee; Kevin D Lance; Mian Chen; Iris O Siguenza; Tejal A Desai; Michael S Conte
Journal:  J Vasc Surg       Date:  2016-03-29       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.